Key facts
- This page summarizes Arvin Yang's Form 4 filing for Mersana Therapeutics, Inc. (MRSN).
- 5 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 18 Jan 2023, 19:29.
Arvin Yang - 13 Jan 2023 Form 4 Insider Report for Mersana Therapeutics, Inc. (MRSN)
- Reporting relationship
- SVP, Chief Medical Officer
- Issuer ticker
- MRSN
- Reported as of
- 13 Jan 2023
- Net transaction value
- -$12,680
- SEC form
- 4
- Accepted by SEC
- 18 Jan 2023, 19:29:00 UTC
- Prior SEC filing
- 02 Dec 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/Alejandra Carvajal, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Arvin Yang filed Form 4 for Mersana Therapeutics, Inc. (MRSN) on 18 Jan 2023.
Change
- Previous filing in this sequence was filed on 02 Dec 2022.
- Current net transaction value: -$12,680.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MRSN
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +7,084
- Change %
- +27%
- Price
- $0.000000
- Shares after
- 33,030
- Date
- 14 Jan 2023
- Ownership
- Direct
- Footnotes
- F1
MRSN
transaction
Common Stock
Sale
- Transaction value
- $12,680
- Shares
- -2,209
- Change %
- -6.7%
- Price
- $5.74
- Shares after
- 30,821
- Date
- 17 Jan 2023
- Ownership
- Direct
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MRSN
transaction
Derivative
Stock option (right to buy)
Award
- Transaction value
- $0
- Shares
- +217,500
- Change %
- Price
- $0.000000
- Shares after
- 217,500
- Date
- 13 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 217,500
- Exercise price
- $6.06
- Footnotes
- F4
MRSN
transaction
Derivative
Restricted stock unit
Award
- Transaction value
- $0
- Shares
- +48,333
- Change %
- Price
- $0.000000
- Shares after
- 48,333
- Date
- 13 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 48,333
- Exercise price
- Footnotes
- F5, F6
MRSN
transaction
Derivative
Restricted stock unit
Options Exercise
- Transaction value
- $0
- Shares
- -7,084
- Change %
- -25%
- Price
- $0.000000
- Shares after
- 21,249
- Date
- 14 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,084
- Exercise price
- Footnotes
- F5, F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 7 footnotes
Footnote F1
Represents shares of common stock received upon the vesting of a portion of the restricted stock units ("RSUs") awarded to the Reporting Person on January 14, 2022.
Footnote F2
Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs reported above. These sales were mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to sell a number of shares of common stock needed to satisfy his tax withholding obligations and does not represent a discretionary trade by the Reporting Person.
Footnote F3
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $5.74 to $5.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Footnote F4
The option shall vest in equal quarterly installments over four years from the date of grant.
Footnote F5
Each RSU represents the contingent right to receive one share of common stock of the Issuer.
Footnote F6
The RSUs shall vest in equal annual installments over four years from the date of grant.
Footnote F7
25% of the total number of RSUs granted vested on January 14, 2023, and the remainder shall vest thereafter in equal annual installments over the next three years.